TAIL FEE COMMON STOCK PURCHASE WARRANT TENAX THERAPEUTICS, INC.Tenax Therapeutics, Inc. • July 8th, 2021 • Pharmaceutical preparations
THIS TAIL FEE COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, __________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above as the Initial Exercise Date (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on July ____, 2026 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Tenax Therapeutics, Inc., a Delaware corporation (the “Company”), up to _________ shares (as subject to adjustment hereunder, the “Warrant Shares”) of the Company’s Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant is being issued pursuant to that certain engagement letter, dated as of July 5, 2020 by and between the Company and H.C. Wainwright & Co., LLC.
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • July 8th, 2021 • Tenax Therapeutics, Inc. • Pharmaceutical preparations
The undersigned hereby provides the following information to the Company and represents and warrants that such information is accurate:
SECURITIES PURCHASE AGREEMENT FOR UNITSSecurities Purchase Agreement for Units • July 8th, 2021 • Tenax Therapeutics, Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement for Units (this “Agreement”) is dated as of July 6, 2021, between Tenax Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
SEPARATION AND GENERAL RELEASE AGREEMENTSeparation and General Release Agreement • July 8th, 2021 • Tenax Therapeutics, Inc. • Pharmaceutical preparations
This Separation and General Release Agreement (the “Agreement”) is made and entered into by and between Tenax Therapeutics, Inc. (the “Company”) and Anthony A. DiTonno (the “Employee”).
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • July 8th, 2021 • Tenax Therapeutics, Inc. • Pharmaceutical preparations • North Carolina
THIS EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”), is made as of July 6, 2021 (the “Effective Date”), by and between Tenax Therapeutics, Inc., a Delaware corporation, with its principal place of business in North Carolina (the “Company”), and Christopher Thomas Giordano (the “Executive”).
